SPACE MEDICINE RESEARCH SERVICE BUSINESS PLAN

I. Executive Summary

Company Description

Aether Health Research, Inc. (Aether) launches in 2026 as a U.S.-based research organization focused on human health in the era of space exploration. We operate in the space medicine and life-sciences sector, offering specialized contract research and consulting services to the new space economy. Our core offerings include in-flight physiology studies, ground-based analog trials, bioinformatics pipelines for astronaut health data, and regulatory-ready risk assessments. We deliver these services from a state-of-the-art laboratory equipped with $1.615 million in advanced diagnostic and analytical tools and staffed by experts in space physiology, bioinformatics, and clinical medicine. One-line: We turn complex space-health data into actionable intelligence for safer, higher-performing crews.

Daily activities include study design, sample processing, longitudinal biomarker analysis, software-driven data integration, and client-facing consulting to translate results into operational protocols. We compete on domain expertise, integrated wet-lab plus informatics capability, and direct operational relevance to commercial and government space missions. Target customers are commercial launch providers, astronaut health programs, and life-sciences contractors supporting crewed missions. Short-term goals: complete facility commissioning and secure three multi-phase contracts by Q4 2026. Long-term goals: become the primary outsourced human-health lab for commercial crewed missions and achieve sustained $10M annual revenue by 2030. One-line: We scale by converting mission health needs into repeatable, contract-ready science and software products.

Problem

Commercial and private long-duration space missions lack actionable, privately sourced health intelligence on the physiological and psychological impacts of microgravity and deep-space radiation, creating measurable risks like bone density loss and cardiovascular deconditioning that current protocols do not fully mitigate.

Institutional research timelines and public data pipelines are slower than new-space deployment schedules, so private habitats and operators face unmet needs for rapid, mission-specific diagnostics and consulting; our 2026 U.S. research organization, with a state-of-the-art lab and $1.615 million in advanced tools, addresses that timing and capability gap. One clear fact: without timely, specialized research support, crew health protocols remain incomplete and insurers charge higher premiums.

Solution

Private and government missions face a critical gap in high-quality biological data and validated countermeasures for long-duration spaceflight—this gap threatens crew health, mission success, and program economics. We offer a comprehensive suite of contract-based research services that analyze and model human physiological responses to microgravity and radiation, develop pharmaceutical and nutritional countermeasures, interpret genomic and proteomic mission datasets, and validate medical technologies and habitat health systems to support operational decision-making.

One-liner: Actionable biological models and validated countermeasures that reduce mission health risk and enable safer sustained space presence.

Mission Statement

We ensure the safety and success of humanity's expansion into space by delivering the world's most advanced and actionable biological health intelligence. We partner with commercial space operators to research, prevent, and treat biological risks in extreme environments, combining rigorous science with rapid, operational solutions. We commit to scientific excellence, commercial agility, and the preservation of human life as the guiding principles of our work.

Key Success Factors

Critical strengths that drive operational scale, margin, and market access.

• Deep technical expertise: multi-disciplinary team solving complex biological challenges.
• $1.615M proprietary lab infrastructure: tangible competitive advantage and capacity.
• Operational breakeven in 19 months: proof of a robust, scalable model.
• Strategic partnerships: launch providers and research institutions supplying steady project pipeline.
• High-margin services: consulting and data analysis drive long-term profitability.

Financial Summary

Brief financial snapshot for the Executive Summary.

Financial requirements: minimum cash shortfall of $1.736M (hit Jul-27); breakeven scheduled for Jul-27 (19 months); total payback 47 months. Anticipated return: IRR 2.56% and ROE 9.06% on the project.

Overall outlook: revenue scales from $1.426M in year one to $13.471M by 2030 with EBITDA turning positive and reaching $6.167M by year five.

Funding Requirements

We require $2,000,000 to buy lab instruments and software, cover a minimum cash deficit, fund 19 months of pre‑breakeven fixed costs and payroll, and reach breakeven (July 2027) while scaling revenue from $1.426M in year one to $13.471M by 2030; initial EBITDA loss is $846,000 (2026), turning to positive EBITDA of $6.167M by year five, with IRR 2.56%, ROE 9.06%, and a 47‑month payback—revenue is diversified across contract research, data services, and consulting retainers.